NeuroOne Appoints Veteran Med-Tech Analyst Jason Mills to Board of Directors

NeuroOne Medical Technologies Corporation has appointed Jason Mills to its Board of Directors, effective December 18, 2025. Mills currently serves as Executive Vice President of Strategy at Penumbra, Inc., where he leads long-range planning, financial planning and analysis, business development, and investor relations for the world's leading thrombectomy company. His appointment represents a strategic addition to NeuroOne's leadership as the company advances its mission to transform surgical diagnosis and treatment of neurological disorders.

The importance of this board appointment lies in Mills' unique combination of corporate executive experience and deep investment analysis background in the medical technology sector. Prior to joining Penumbra, Mills spent over two decades as a dedicated med-tech investment analyst, including more than 13 years as Managing Director and head of the medical technology equity research practice at Canaccord Genuity. During this time, he prepared financial models and forecasts, published research, and conducted due diligence on numerous public and private companies in the medical technology space.

NeuroOne CEO Dave Rosa emphasized the value Mills brings to the company, stating that his firsthand knowledge of the industry combined with investment and capital markets expertise will be critical as NeuroOne progresses on its clinical and corporate goals. Mills has received recognition for his analytical work, including being ranked the #2 Medical Devices analyst in The Wall Street Journal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts.

For investors and the medical technology industry, Mills' appointment signals NeuroOne's commitment to strengthening its strategic direction and corporate governance. As Paul Buckman, Chairman of the Board of Directors noted, Mills will serve on both the Compensation and Nominating & Corporate Governance Committees while helping expand the company's reach in transforming neurological disorder treatment. This move could potentially accelerate NeuroOne's development of minimally invasive solutions for conditions including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain.

The broader implication for patients and healthcare providers is that enhanced strategic leadership could potentially speed the development and commercialization of NeuroOne's technologies, which aim to improve patient outcomes while reducing procedural costs. The company's work in EEG recording, monitoring, ablation, drug delivery, and stimulation solutions addresses significant unmet needs in neurological care. For more information about NeuroOne's technologies and development pipeline, visit https://nmtc1.com.